Secondary acute promyelocytic leukemia following chemotherapy for gastric cancer: A case report
| Autor: | Li-Juan Xiu, Zhi-Feng Qin, Yu-Qi Zhou, Ying-Cheng Zhang, Yong-Jin Li, Sun Yuwei, Jun Shi, Bing Yan, Pin-Kang Wei, Xuan Liu |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2015 |
| Předmět: |
Acute promyelocytic leukemia
Male medicine.medical_specialty Myeloid Organoplatinum Compounds medicine.medical_treatment Biopsy Case Report Gastroenterology Capecitabine Leukemia Promyelocytic Acute Predictive Value of Tests Risk Factors Stomach Neoplasms Internal medicine Antineoplastic Combined Chemotherapy Protocols Granulocyte Colony-Stimulating Factor medicine Biomarkers Tumor Humans Aged Chemotherapy business.industry Remission Induction Myeloid leukemia Cancer General Medicine medicine.disease Oxaliplatin Leukemia medicine.anatomical_structure Treatment Outcome Karyotyping Immunology business Tomography X-Ray Computed medicine.drug |
| Popis: | Therapy-related acute myeloid leukemia (t-AML) refers to a heterogeneous group of myeloid neoplasms that develop in patients following extensive exposure to either cytotoxic agents or radiation. The development of t-AML has been reported following treatment of cancers ranging from hematological malignancies to solid tumors; however, to our knowledge, t-AML has never been reported following treatment of gastric cancer. In this study, we report the development of t-acute promyelocytic leukemia in a cT4N1M0 gastric cancer patient after an approximate 44 mo latency period following treatment with 4 cycles of oxaliplatin (OXP) (85 mg/m(2) on day 1) plus capecitabine (1250 mg/m(2) orally twice daily on days 1-14) in combination with recombinant human granulocyte-colony stimulating factor treatment. Karyotype analysis of the patient revealed 46,XY,t(15;17)(q22;q21)[15]/46,idem,-9,+add(9)(p22)[2]/46,XY[3], which, according to previous studies, includes some "favorable" genetic abnormalities. The patient was then treated with all-trans retinoic acid (ATRA, 25 mg/m(2)/d) plus arsenic trioxide (ATO, 10 mg/d) and attained complete remission. Our case illuminated the role of certain cytotoxic agents in the induction of t-AML following gastric cancer treatment. We recommend instituting a mandatory additional evaluation for patients undergoing these therapies in the future. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|